VNDA
Vanda Pharmaceuticals Inc
$
4.400
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
4.420
Open
4.400
VWAP
4.34
Vol
604.37K
Mkt Cap
260.03M
Low
4.270
Amount
2.62M
EV/EBITDA(TTM)
--
Total Shares
58.20M
EV
-28.55M
EV/OCF(TTM)
--
P/S(TTM)
1.22
Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company’s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
63.25M
+18.92%
-0.380
+375%
65.73M
+31.36%
-0.150
-70%
73.73M
+40.2%
0.020
-104.35%
Estimates Revision
The market is revising Downward the revenue expectations for Vanda Pharmaceuticals Inc. (VNDA) for FY2025, with the revenue forecasts being adjusted by -0.37% over the past three months. During the same period, the stock price has changed by 4.76%.
Revenue Estimates for FY2025
Revise Downward
-0.37%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-0.09%
In Past 3 Month
Stock Price
Go Up
+4.76%
In Past 3 Month
1 Analyst Rating
Wall Street analysts forecast VNDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VNDA is 20.00 USD with a low forecast of 20.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.400
Low
20.00
Averages
20.00
High
20.00
Current: 4.400
Low
20.00
Averages
20.00
High
20.00
B. Riley
NULL -> Buy
initiated
$11
2025-11-05
New
Reason
B. Riley
Price Target
$11
2025-11-05
New
initiated
NULL -> Buy
Reason
B. Riley initiated coverage of Vanda Pharmaceuticals with a Buy rating and $11 price target. The firm says Vanda is a commercial-stage turnaround story trading at a "historic discount." The company is heading into two potential approvals within three months and "clearing of multiple overhangs that have kept investors on the sidelines," the analyst tells investors in a research note. It believes the stock's current negative enterprise value represents an attractive entry point.
Cantor Fitzgerald
Overweight
initiated
$13
2025-05-14
Reason
Cantor Fitzgerald
Price Target
$13
2025-05-14
initiated
Overweight
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$20
2025-04-01
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$20
2025-04-01
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Maintains
$18 → $20
2025-02-18
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$18 → $20
2025-02-18
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$18
2025-02-04
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$18
2025-02-04
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$18
2025-01-28
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$18
2025-01-28
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Vanda Pharmaceuticals Inc (VNDA.O) is -2.76, compared to its 5-year average forward P/E of -18.74. For a more detailed relative valuation and DCF analysis to assess Vanda Pharmaceuticals Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-18.74
Current PE
-2.76
Overvalued PE
157.78
Undervalued PE
-195.25
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
4.83
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
11.53
Undervalued EV/EBITDA
-1.87
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Strongly Overvalued
5Y Average PS
2.03
Current PS
4.41
Overvalued PS
2.89
Undervalued PS
1.17
Financials
Annual
Quarterly
FY2025Q3
YoY :
+18.06%
56.26M
Total Revenue
FY2025Q3
YoY :
+184.40%
-31.28M
Operating Profit
FY2025Q3
YoY :
+324.23%
-22.59M
Net Income after Tax
FY2025Q3
YoY :
+322.22%
-0.38
EPS - Diluted
FY2025Q3
YoY :
+115.62%
-31.79M
Free Cash Flow
FY2025Q3
YoY :
+0.73%
91.63
Gross Profit Margin - %
FY2025Q3
YoY :
+309.96%
-39.11
FCF Margin - %
FY2025Q3
YoY :
+259.44%
-40.15
Net Margin - %
FY2025Q3
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
32.1K
USD
1
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
1
41.5K
USD
Months
6-9
5
275.9K
USD
Months
0-12
5
196.3K
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
32.1K
USD
1
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
1
41.5K
USD
Months
6-9
5
275.9K
USD
Months
0-12
5
196.3K
USD
Months
VNDA News & Events
Events Timeline
2025-10-29 (ET)
2025-10-29
16:02:29
Vanda Pharmaceuticals announces Q3 earnings per share of 38 cents, below consensus estimate of 45 cents.
2025-10-01 (ET)
2025-10-01
17:08:17
Vanda Pharmaceuticals and FDA Reach Agreement to Settle Disputes Over Hetlioz and Tradipitant
2025-09-25 (ET)
2025-09-25
08:05:31
Vanda Pharmaceuticals' Hetlioz Achieves Key Goals in Insomnia Research
Sign Up For More Events
Sign Up For More Events
News
9.0
11-07Yahoo FinancePinnedOctober Recap: 10 Key Health Press Releases
4.0
11-05SeekingAlphaVanda Receives New Buy Rating from B. Riley Due to 'Historic Discount'
4.0
11-05BenzingaDocebo Analyst Starts Coverage Optimistically; Check Out the Top 3 Initiations for Wednesday
Sign Up For More News
People Also Watch
GHG
GreenTree Hospitality Group Ltd
1.960
USD
-2.49%
HITI
High Tide Inc
2.960
USD
+2.07%
LIEN
Chicago Atlantic BDC Inc
10.080
USD
0.00%
INSE
Inspired Entertainment Inc
8.130
USD
+0.25%
JYD
Jayud Global Logistics Ltd
3.760
USD
-3.59%
MTA
Metalla Royalty & Streaming Ltd
6.480
USD
+3.51%
FDBC
Fidelity D&D Bancorp Inc
44.220
USD
+1.12%
MVBF
MVB Financial Corp
26.500
USD
-0.08%
PRQR
ProQR Therapeutics NV
2.220
USD
+0.45%
ARBE
Arbe Robotics Ltd
1.630
USD
+0.62%
FAQ
What is Vanda Pharmaceuticals Inc (VNDA) stock price today?
The current price of VNDA is 4.4 USD — it has decreased -0.23 % in the last trading day.
What is Vanda Pharmaceuticals Inc (VNDA)'s business?
What is the price predicton of VNDA Stock?
What is Vanda Pharmaceuticals Inc (VNDA)'s revenue for the last quarter?
What is Vanda Pharmaceuticals Inc (VNDA)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Vanda Pharmaceuticals Inc (VNDA)'s fundamentals?
How many employees does Vanda Pharmaceuticals Inc (VNDA). have?